Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,410 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00243009 | Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery | terminated | Phase 2 | 1 | OHSU Knight Cancer InstituteOTHER | 1 | May 28, 2012 | clinicaltrials |
| NCT00311467 | Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma | terminated | Phase 3 | 172 | Central European Cooperative Oncology GroupOTHER | 1 | May 16, 2012 |
| clinicaltrials |
| NCT00100685 | Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | terminated | Phase 2 | 48 | AbbottINDUSTRY | 1 | Apr 27, 2012 | clinicaltrials |
| NCT01033981 | Cost Effectiveness Of Sunitinib In Central America And Caribbean | terminated | — | 4 | PfizerINDUSTRY | 1 | Apr 19, 2012 | clinicaltrials |
| NCT00485563 | A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 12 | EndocyteINDUSTRY | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00561912 | Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 26, 2011 | clinicaltrials |
| NCT00221728 | Comparison Between Surgery and Radiofrequency for Treatment of Renal Tumors | terminated | Phase 2 / Phase 3 | 160 | University Hospital, BordeauxOTHER | 1 | May 28, 2010 | clinicaltrials |
| NCT00277316 | Study of XL999 in Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 11 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 19, 2010 | clinicaltrials |
| NCT00323791 | Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer | terminated | Phase 2 | 100 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Dec 11, 2009 | clinicaltrials |
| NCT00491738 | A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | terminated | Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Apr 10, 2009 | clinicaltrials |
| NCT00417677 | A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 124 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 28, 2007 | clinicaltrials |
| NCT00131651 | ATN-161 in Advanced Renal Cell Cancer | terminated | Phase 2 | 36 | AttenuonINDUSTRY | 1 | Dec 6, 2007 | clinicaltrials |
| NCT00151645 | Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. | terminated | Phase 2 | 36 | Rennes University HospitalOTHER | 1 | Jan 2, 2006 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2012source: clinicaltrials